Navigation Links
First demonstration of new hair follicle generation in an animal model

Researchers at the University of Pennsylvania School of Medicine have found that hair follicles in adult mice regenerate by re-awakening genes once active only in developing embryos. These findings provide unequivocal evidence for the first time that, like other animals such as newts and salamanders, mammals have the power to regenerate. These findings are published in the May 17 issue of Nature.

A better understanding of this process could lead to novel treatments for hair loss, other skin and hair disorders, and wounds.

“We showed that wound healing triggered an embryonic state in the skin which made it receptive to receiving instructions from wnt proteins,?says senior author George Cotsarelis, MD, Associate Professor of Dermatology. “The wnts are a network of proteins implicated in hair-follicle development.?

Researchers previously believed that adult mammal skin could not regenerate hair follicles. In fact, investigators generally believe that mammals had essentially no true regenerative qualities. (The liver can regenerate large portions, but it is not de novo regeneration; some of the original liver has to remain so that it can regenerate.)

In this study, researchers found that wound healing in a mouse model created an “embryonic window?of opportunity. Dormant embryonic molecular pathways were awakened, sending stem cells to the area of injury. Unexpectedly, the regenerated hair follicles originated from non-hair-follicle stem cells.

“We’ve found that we can influence wound healing with wnts or other proteins that allow the skin to heal in a way that has less scarring and includes all the normal structures of the skin, such as hair follicles and oil glands, rather than just a scar,?explains Cotsarelis.

By introducing more wnt proteins to the wound, the researchers found that they could take advantage of the embryonic genes to promote hair-follicle growth, thus making skin regenerate instead of just rep
'"/>

Source:University of Pennsylvania School of Medicine


Page: 1 2

Related biology news :

1. Timing is everything: First step in protein building revealed
2. Emory Eye Center Implants Its First Retinal Chips In Patients With Retinitis Pigmentosa
3. First atlas of key brain genes could speed research on cancer, neurological diseases
4. First-ever Compounds To Target Only Metastatic Cells Are Highly Effective Against Breast, Prostate, And Colon Cancers
5. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
6. First real-time view of developing neurons reveals surprises, say Stanford researchers
7. Breast-Cancer Risk Linked to Exposure to Traffic Emissions at Menarche, First Birth
8. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
9. First frozen egg baby born in Canada
10. Human Cells Filmed Instantly Messaging for First Time
11. First North American Encapsulated Islet Transplant without Long-term Immune Suppression into a Patient with Type 1 Diabetes

Post Your Comments:
(Date:11/23/2009)...INCINNATINew research presents strong evidence tha...to both outdoor traffic-related pollution and indo...than one or the other exposure alone. , Enviro...cinnati (UC) College of Medicine have shown that c...ated particles and indoor endotoxin during early l...
(Date:11/23/2009)... A new study by the Wildlife Conservation Society ...ge swamp in the Republic of Congopart of the "moth...last yearare becoming increasingly threatened by g...y recommends protection of the swamp forests adjac...serve after recent surveys confirmed that high den...
(Date:11/23/2009)... AMES, Iowa - The only swine vaccine available for... herd infected with the virus. The vaccination mar... herd diagnosed with the pandemic flu., Iowa Sta...cience, developed the vaccine this summer and has ...in Iowa, Kansas and Illinois for several weeks., ...
Breaking Biology News(10 mins):Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later 2A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Iowa State researcher produces, ships only H1N1 vaccine available for swine 2Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 1Eli Lilly 26 Company and ScinoPharm Taiwan Ltd Announce Settlement of Gemcitabine Litigation 13272 2Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 1Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 2Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 3Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 4Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 5Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 6Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 7Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 8Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 9Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 10Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 11Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 12Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 13Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 14Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 15Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 16Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 17Mylan Reports Adjusted Diluted EPS of 240 32 for the Quarter Ended June 30 2009 13271 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 1Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 2Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 3Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 4Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 5Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 6Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 7Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 8Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 9Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 10Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 11Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 12Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 13Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 14Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 15Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 16Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 17Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 18Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 19Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 20Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 21Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 22Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 23Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 24Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 25Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 26Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 27Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 28Tyco International Reports Third Quarter Earnings from Continuing Operations Before Special Items of 240 58 Per Share and GAAP Earnings of 240 51 Pe 53185 29
..., 115 scientists from around the world report in t...ne" of data on a tiny green alga called Chlamydomo...single-celled Chlamydomonas, a slimy organism that... genes, and scientists now know 95 percent of the ...ew less than 2 percent. , "It,s like having a dic...
...nia have discovered that the nuclei of human stem ...han hard, making it easier for stem cells to migra... but ultimately to put human genes in the correct ...Researchers pulled cell nuclei into microscopic gl...d the shear of the DNA and associated proteins by ...
...Energys Office of Science today released a compreh...cilities for the Future of Science: A Twenty-Year ...t progress in deploying the scientific facilities ...pture world scientific leadership, extend the fron...ons. , When it was published four years ago, the ...
Other Biology News:Study involving more than 100 scientists provides new insights on green algae 2Study involving more than 100 scientists provides new insights on green algae 3Study involving more than 100 scientists provides new insights on green algae 4Stem cell nuclei are soft 'hard drives,' Penn study finds 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5
(Date:11/24/2009)...HealthRoboticstodayannounced,thatithasformedanewCa...hisrecentlyformedToronto-basedcompanywilloperateun...install,andsupport,HealthRobotics,i.v.RoomoftheFut...feringsi.v.STATION(TM),i.v.SOFT(TM),andOMM(TM).,He...n"asneeded,basis"toitsstrategicpartnershipswithMcK...
(Date:11/24/2009)...--CellTherapeutics,Inc.(CTI)(NasdaqandMTA:CTIC)man...hCareConference.TheconferencewillbeheldDecember1-2...tonTuesday,December1at11:00a.m.EasternTimeinHolmes...llbeavailableat www.celltherapeutics.com ,anditwil...rayHealthCareConference,NewYorkPalaceHotel,Holmes1...
(Date:11/23/2009)...unication, computation and more powerful ways to e...antum states as carriers of information is an extr...hown, mathematically, how to gently tease out unwa... the information intact. Their work is reported in...d highlighted with a Viewpoint in Physics ( http...
(Date:11/23/2009)...stCall/-YMBioSciencesInc.(NYSEAmex: YMI ;TSX:YM),a...sandadvancesadiverseportfolioofpromisingcancer-rel...rtedthatCytopia(ASX:CYT)hascommencedenrollmentofaP...isteredJAK1/JAK2inhibitor.Thetrialisbeingconducted...CytopiaintoYMhasbeenpreviouslyannouncedandispendin...
Breaking Biology Technology:Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 2YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 3YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA 4
...d leader in,the rapidly evolving field of cancer m...appointed Hessel J. H. M. Lindenbergh as Chairman ... former member of the managing board of ING,Group ...e supervisory board,of NIB Capital N.V. and board ...l and Gamma Holding. Mr. Lindenbergh is also a mem...
...ls,Inc. (Amex: ANX ), a biopharmaceutical researc...ng proprietary product candidates for the treatmen...ay that Evan M. Levine,ADVENTRX,s chief executive ...y Partners, Fifth Annual Growth Conference on Wedn...ylight Time, 5:30pm Eastern,Daylight Time. The con...
...- Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI , ...urable decision from the Intellectual Property Off... & Johnson,s subsidiary, Conor Medsystems,Inc. ("C...3799, which,pertains to compositions comprising a ...aclitaxel-eluting stents. In a decision dated Sept...
Other Biology Technology:Agendia BV Appoints Mr. Hessel Lindenbergh as Chairman of its Supervisory Board 2ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners' Fifth Annual Growth Conference 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 2Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 3Angiotech receives favourable patent decision from New Zealand's Intellectual Property Office 4
Mouse Anti-Cytokeratin 5 / 14 Monoclonal Antibody, Unconjugated, Clone LH8 from Abcam
Rabbit Anti-Human C1QC Polyclonal Antibody, Unconjugated from Atlas Antibodies
Mouse Anti-Human Integrin alpha 2b / beta 3 Monoclonal Antibody, Unconjugated, Clone CRC64 from Abcam
Rabbit Anti-NCoR2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: